Retatrutide

Retatrutide is an innovative long-acting triple agonist peptide that simultaneously activates GLP‑1, GIP and glucagon receptors (GCGR). It features fatty acid lipid modification for prolonged metabolic stability and half-life compared to dual-target incretin peptides.

Our Retatrutide is produced via solid-phase peptide synthesis and high-purity RP-HPLC refining, presented as uniform white lyophilized powder. Activating three key metabolic pathways at once delivers stronger appetite suppression, fat loss and glycemic control effects, making it a core research material for next-generation weight management and diabetes mechanism exploration. Every batch undergoes HPLC purity testing and high-resolution LC-MS molecular weight identification, full batch-specific COA, chromatograms and mass spectra are provided to ensure consistent and repeatable lab experimental results.

2. Available Specifications

SKU Options:

NJ100: 100mg per vial, 10 vials per kit
NJ500: 500mg per vial, 10 vials per kit
NJ1000: 1000mg per vial, 10 vials per kit

Custom bulk synthesis and customized single-vial dosage are available upon customer inquiry for large-scale animal trials and compound formulation research. It is also used as core raw material for RTT60 compound peptide (Retatrutide 20mg + Tirzepatide 40mg).

3. Core Preclinical Research Applications

Type 2 Diabetes & Glycemic Balance Research

Triple-receptor activation promotes glucose-dependent insulin secretion, suppresses glucagon release and stabilizes long-term blood glucose levels; ideal reagent for pancreatic beta-cell protection and insulin resistance rodent model studies.
Severe Obesity & Adipose Metabolism Research

Synergistic inhibition of food intake, accelerated lipolysis of visceral fat and reduced calorie absorption; widely used to compare weight-loss efficacy against Tirzepatide, Semaglutide and Cagrilintide analogues.
Hepatic Metabolic Disorder Research

Reduces liver fat accumulation, improves hepatic insulin sensitivity, suitable for NAFLD and fatty liver disease exploratory mechanism experiments.
Cardiometabolic Protection Research

Regulates blood lipid profiles and alleviates vascular inflammatory damage for cardiovascular risk factor research.
Multi-Agonist Compound Peptide Stack Research

Commonly compounded with Tirzepatide to develop triple/quadruple target composite metabolic peptide kits such as RTT60 for comparative pathway research.

4. Strict Quality Control Standards

HPLC purity ≥99% gradient reverse-phase chromatography
LC-MS full molecular weight identity verification
Endotoxin level controlled below 0.1 EU/mg
Independent batch COA, HPLC chromatogram and MS spectrum attached
Full detection of truncated impurities, lipidation byproducts, residual solvents and heavy metals
Stability verification under thermal, oxidative and light stress conditions

5. Storage & Shipping Guidance

Lyophilized powder storage: Seal tightly and store at -20°C, avoid light, high temperature and humid environment; stable for 24 months under proper sealed preservation.
After reconstitution: Store at 2–8°C, aliquot into small portions to avoid repeated freeze-thaw cycles that cause lipid modification degradation and loss of biological activity.
Global delivery: Low-temperature insulated cold-chain packaging protects peptide activity during long-distance cross-border transportation.
Technical service: Our R&D team provides reconstitution protocols, storage standards and experimental scheme consultation within 24 working hours.

6. Important Disclaimer

This lyophilized Retatrutide peptide powder is for laboratory research use only. It is not approved for human injection, oral administration, clinical treatment or veterinary medication. All product data is solely for academic lab exploratory research.